Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
BERKELEY, Calif., Dec. 27, 2016 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2017, at 10:00 am Pacific Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 [email protected]
